European CHMP Issues Positive Opinion On Cymbalta For The Treatment Of Generalised Anxiety Disorder
Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion supporting the approval of Cymbalta® (duloxetine hydrochloride) for the treatment of Generalised Anxiety Disorder (GAD).
